卡维地洛与普萘洛尔降低肝硬化患者门静脉压力的随机多中心开放标签研究
这项随机多中心开放标签研究纳入110例基线肝静脉压力梯度(HVPG)>12 mm Hg的肝硬化患者,比较卡维地洛与普萘洛尔用药6周后的血流动力学应答。意向治疗分析中两组应答比例差异未达统计学显著(卡维地洛49.1% vs 普萘洛尔30.9%,P=0.08);但在MELD评分≥15的患者中卡维地洛应答显著优于普萘洛尔(7/12,58.3% vs 0/10,0%,P=0.005)。作者认为卡维地洛总体无明确优势,但在MELD评分≥15的晚期肝硬化患者中可能更有效,且可能伴随副作用风险增加。
要点
- 意向治疗分析中卡维地洛与普萘洛尔应答比例差异未达统计学显著(49.1% vs 30.9%,P=0.08)。
- MELD评分≥15者卡维地洛应答显著优于普萘洛尔(7/12,58.3% vs 0/10,0%,P=0.005)。
- 卡维地洛组严重不良事件较多,但药物相关不良事件无差异。
核心结论
- 总体而言卡维地洛较普萘洛尔无明确优势,但在MELD评分≥15的晚期肝硬化患者中可能更有效降低门静脉压力梯度。
- 作者认为这一潜在获益可能以副作用风险增加为代价,需要更长期结局数据来理解相对风险获益。
研究设计与样本
- 随机、多中心、开放标签研究,共纳入110例基线HVPG>12 mm Hg的肝硬化患者,随机接受卡维地洛或普萘洛尔。
- 每日用药6周后重复测量HVPG,主要终点为HVPG较基线下降≥20%或<12 mm Hg。
主要发现
- 意向治疗分析中卡维地洛组应答比例49.1% vs 普萘洛尔组30.9%,差异未达统计学显著(P=0.08)。
- MELD评分≥15患者中卡维地洛应答7/12(58.3%)vs 普萘洛尔0/10(0%),P=0.005。
- Child-Pugh评分≥9患者中卡维地洛46.2% vs 普萘洛尔0%(P=0.046)。
- 腹水存在对答率有显著影响(51.5% vs 24.2%,P=0.042)。
- 校正多重比较后,MELD评分≥15是这些事后分组中唯一显著的应答预测因素(P=0.005)。
临床怎么用
- 作者认为卡维地洛在MELD评分≥15的晚期肝硬化患者中可能更有效降低门静脉压力梯度,但该潜在获益可能伴随副作用风险增加。
- 作者指出需要更长期结局数据来理解卡维地洛的相对风险获益。
局限性
- 作者指出需要更长期结局数据来理解卡维地洛的相对风险获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis. More recent data suggest that carvedilol may be more effective for reducing the hepatic venous pressure gradient (HVPG) than propranolol. The primary aim of this study was to evaluate the hemodynamic response to carvedilol compared with propranolol. METHODS: A total of 110 patients with a baseline HVPG value >12 mm Hg were allocated randomly to receive either carvedilol or propranolol. The HVPG measurement was repeated after 6 weeks of daily medication. The primary end point was a ≥20% fall in HVPG compared with baseline or <12 mm Hg. RESULTS: The difference in the proportion of responders in the carvedilol (49.1%) vs. propranolol (30.9%) groups did not reach statistical significance in the intention-to-treat analysis (P=0.08). However, among patients with a model for end-stage liver disease (MELD) score ≥15, carvedilol resulted in a significantly greater response than that of propranolol (7/12, 58.3% vs. 0/10, 0%; P=0.005). Similarly, carvedilol was superior to propranolol in patients with Child-Pugh score ≥9 (46.2 vs. 0%; P=0.046). The presence of ascites also had a significant influence on the response rate (51.5 vs. 24.2%; P=0.042). A MELD score ≥15 was the only significant predictor of response among these post hoc groups after adjusting for multiple comparisons (P=0.005). Severe adverse events were higher in the carvedilol group although drug-associated adverse events were not different. CONCLUSIONS: Overall, carvedilol offered no clear advantage over propranolol but it may be more effective in advanced cirrhotic patients with a MELD score≥15 in reducing the portal pressure gradient. However, this potential benefit may come with a cost of increased risk of side-effects and outcome data over a longer term is needed to understand the relative risk benefit.
引用
- Kim SG, Kim TY, Sohn JH, et al. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. Am J Gastroenterol. 2016. PMID: 27575713. doi:10.1038/ajg.2016.327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。